Revocation of New York Ruling Letter (NY) N319324; Classification of Transducer Arrays
No revocation or modification of this ruling appears in the Customs Bulletin issues read here (Nov 6, 2024 through Nov 18, 2026), where CBP publishes most such actions. That is not confirmation that the ruling is still in effect. Confirm its status with CBP before relying on it (ruling on CBP CROSS).
Key passages, quoted from the ruling
- If the subject merchandise is classified under heading 9018, HTSUS, it is therefore excluded from heading 8543, HTSUS.
Ruling text
This is our decision in response to your request of February 26, 2025, filed on behalf of your client Amphenol Critical Medical Technologies, LLC (formerly Providien Device Assembly, LLC), for the revocation of New York Ruling Letter (NY) N319324, issued on May 25, 2021. There, U.S. Customs and Border Protection (CBP) classified certain transducer arrays from Israel under heading 8543 of the Harmonized Tariff Schedule of the United States (HTSUS).
You request that CBP reclassify the merchandise at issue under heading 9018, HTSUS. We reviewed NY N319324 and determined that it was in error and proposed revocation of said ruling.
Pursuant to Section 625(c)(1), Tariff Act of 1930 (19 U.S.C. § 1625(c)(1)), as amended by Section 623 of Title VI (Customs Modernization) of the North American Free Trade Agreement Implementation Act, Pub. L. No. 103-182, 107 Stat. 2057, 2186 (1993), notice of the proposed action was published on January 21, 2026, in Volume 60, Number 3, of the Customs Bulletin. No comments were received in response to this notice. Accordingly, and for the reasons set forth below, CBP is revoking NY N319324.
FACTS: The subject merchandise consists of certain transducer arrays that are used with the “Novocure” portable therapy delivery system to treat certain types of cancer. In your request, you note that there are two models of the therapy delivery system – the “Optune Gio” and the “Optune Lua” – and each model primarily consists of two components: (1) a separately- presented electric field generator (i.e., a battery) and (2) the transducer arrays subject to this decision.
Both the Optune Gio and Optune Lua are wearable, portable devices that generate tumor treating fields (“TTFields”). TTFields are mild, alternating electric fields delivered through adhesive patches (i.e., the transducer arrays), which are placed on the patient’s skin where a 1 tumor is located. The TTFields disrupt the division of cancer cells by attracting and repelling charged proteins during mitosis, thereby inhibiting tumor growth while minimally affecting 2 normal, healthy cells.
The Optune Gio is designed to treat glioblastoma multiforme (GBM), an 3 aggressive and common form of brain tumor. The Gio’s transducer arrays are placed on the patient’s shaved scalp. The Optune Lua, on the other hand, targets metastatic non-small cell lung cancer (mNSCLC); its transducer arrays are placed on the front or back of the patient’s chest.
The transducer arrays for both the Gio and Lua connect directly to the electric field generator and are made up of hydrogel, “minipads,” ceramic disks, flexible circuit boards, and medical tape.
The text above is an excerpt. The official ruling, with its letterhead, signature and any attachments, is on CBP CROSS (H345915).